• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Flamel Technologies tops Q3 revenue, EPS estimate

November 7, 2016 By Sarah Faulkner

Flamel Technologies tops Q3 revenue, EPS estimateShares in Flamel Technologies (NSDQ:FLML) rose today after the pharmaceutical company met expectations on Wall Street with its 3rd quarter results.

The Venissieux, France-based company posted a loss of -$22.3 million on sales of $32.1 million for the 3 months ended Sept. 30, for bottom-line growth of 20% despite a sales loss of 32% compared with the same period last year.

Adjusted to exclude 1-time items, losses per share were -8¢, ahead of consensus on The Street, where analysts were looking for sales of $30.7 million.

“Our base business, consisting of Bloxiverz (neostigmine methylsulfate), Vazculep (phenylephrine hydrochloride) and Akovaz (ephedrine sulfate), remained strong during the 3rd quarter with revenues coming in just above top line consensus,” CEO Michael Anderson said in prepared remarks. “Although we were able to maintain strong share in the neostigmine market at about 40% during the 3rd quarter, the overall market volume slightly declined. This, in addition to a small loss in price, resulted in lower quarter over quarter sales of Bloxiverz, at $15.6 million for the quarter. The phenylephrine business remained stable with 3rd quarter 2016 sales of $9.3 million, relatively in line with the previous quarter after adjusting for our change in revenue recognition. As expected in the 3rd quarter, we launched Akovaz, the 1st FDA-approved ephedrine sulfate injection. Akovaz added $5.6 million in revenues, partially offsetting some weakness in the neostigmine market which, as we outlined at the beginning of the year, was expected with increased competition. I am very pleased with the on-time and successful launch of Akovaz as it once again demonstrates our ability to identify, develop and launch commercially viable pharmaceutical products. Given that we launched later in the quarter, we are off to a good start.”

Flamel boosted its full-year revenue guidance range to $133 to $143 million, up from its previous guidance range of $125 to $140 million.

FLML shares were trading at $9.62 apiece today in afternoon trading, up 1.05%.

Filed Under: Drug-Device Combinations, Featured, Hydrogels, MassDevice Earnings Roundup, Pharmaceuticals Tagged With: Flamel Technologies

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS